Cargando…

From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?

BACKGROUND: Neoadjuvant chemotherapy (NAC) has been widely performed in the treatment of colorectal cancer liver metastasis (CRLM) patients, but the optimal timing of surgery after NAC is unclear. The aim of this study was to investigate the optimal timing of surgery. METHODS: From December 2010 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qichen, Mao, Rui, Zhao, Jianjun, Bi, Xinyu, Li, Zhiyu, Huang, Zhen, Zhang, Yefan, Zhou, Jianguo, Zhao, Hong, Cai, Jianqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643690/
https://www.ncbi.nlm.nih.gov/pubmed/32886456
http://dx.doi.org/10.1002/cam4.3283
_version_ 1783606328319541248
author Chen, Qichen
Mao, Rui
Zhao, Jianjun
Bi, Xinyu
Li, Zhiyu
Huang, Zhen
Zhang, Yefan
Zhou, Jianguo
Zhao, Hong
Cai, Jianqiang
author_facet Chen, Qichen
Mao, Rui
Zhao, Jianjun
Bi, Xinyu
Li, Zhiyu
Huang, Zhen
Zhang, Yefan
Zhou, Jianguo
Zhao, Hong
Cai, Jianqiang
author_sort Chen, Qichen
collection PubMed
description BACKGROUND: Neoadjuvant chemotherapy (NAC) has been widely performed in the treatment of colorectal cancer liver metastasis (CRLM) patients, but the optimal timing of surgery after NAC is unclear. The aim of this study was to investigate the optimal timing of surgery. METHODS: From December 2010 to May 2018, 101 consecutive patients who received NAC followed by liver resection for CRLM were included in this study. The main outcome parameters were pathological response, progression‐free survival (PFS), and overall survival (OS). The effect of time to surgery (TTS) on patient outcomes, defined as a high TTS and a low TTS according to an X‐tile analysis, was investigated. To adjust for potential selection bias, propensity score matching at 1:2 was performed with two high TTS patients matched to one low TTS patient. Kaplan‐Meier curves, logistic regression analyses, and Cox regression models were used for the data analysis. RESULTS: The optimal cut‐off value for the TTS was 5 weeks by X‐tile analysis. The patients in this study were divided into low (≤5 weeks, n = 27) and high (>5 weeks, n = 74) TTS groups. Patients with a high TTS were more likely to have an unfavorable pathological response (75.7% vs 48.1%, P = .008). In multivariate analysis, a low TTS significantly predicted a better pathological response (OR = 3.397, 95% CI: 1.116‐10.344, P = .031). Compared to patients with a high TTS, patients with a low TTS had significantly better PFS (P < .001, mPFS: 16 months vs 7 months) and better OS (P = .037, mOS: not reached vs 36 months). Multivariate analysis revealed that a TTS > 5 weeks was an independent predictor of decreased PFS (HR = 2.041, 95% CI: 1.152‐3.616, P = .014) but not OS. After propensity matching, the patients with a low TTS had significantly better PFS (P < .001, mPFS: 18.2 months vs 10 months) and an equivalent OS (P = .115, mOS: not reached vs 41 months). Multivariate analysis revealed that a TTS > 5 weeks was an independent predictor of decreased PFS (HR = 3.031, 95% CI: 1.494‐6.149, P = .002) but not OS. CONCLUSION: The longer TTS after the completion of NAC may be disadvantageous for a favorable pathological response and long‐term PFS. These results should be validated prospectively in a randomized trial.
format Online
Article
Text
id pubmed-7643690
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76436902020-11-13 From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing? Chen, Qichen Mao, Rui Zhao, Jianjun Bi, Xinyu Li, Zhiyu Huang, Zhen Zhang, Yefan Zhou, Jianguo Zhao, Hong Cai, Jianqiang Cancer Med Clinical Cancer Research BACKGROUND: Neoadjuvant chemotherapy (NAC) has been widely performed in the treatment of colorectal cancer liver metastasis (CRLM) patients, but the optimal timing of surgery after NAC is unclear. The aim of this study was to investigate the optimal timing of surgery. METHODS: From December 2010 to May 2018, 101 consecutive patients who received NAC followed by liver resection for CRLM were included in this study. The main outcome parameters were pathological response, progression‐free survival (PFS), and overall survival (OS). The effect of time to surgery (TTS) on patient outcomes, defined as a high TTS and a low TTS according to an X‐tile analysis, was investigated. To adjust for potential selection bias, propensity score matching at 1:2 was performed with two high TTS patients matched to one low TTS patient. Kaplan‐Meier curves, logistic regression analyses, and Cox regression models were used for the data analysis. RESULTS: The optimal cut‐off value for the TTS was 5 weeks by X‐tile analysis. The patients in this study were divided into low (≤5 weeks, n = 27) and high (>5 weeks, n = 74) TTS groups. Patients with a high TTS were more likely to have an unfavorable pathological response (75.7% vs 48.1%, P = .008). In multivariate analysis, a low TTS significantly predicted a better pathological response (OR = 3.397, 95% CI: 1.116‐10.344, P = .031). Compared to patients with a high TTS, patients with a low TTS had significantly better PFS (P < .001, mPFS: 16 months vs 7 months) and better OS (P = .037, mOS: not reached vs 36 months). Multivariate analysis revealed that a TTS > 5 weeks was an independent predictor of decreased PFS (HR = 2.041, 95% CI: 1.152‐3.616, P = .014) but not OS. After propensity matching, the patients with a low TTS had significantly better PFS (P < .001, mPFS: 18.2 months vs 10 months) and an equivalent OS (P = .115, mOS: not reached vs 41 months). Multivariate analysis revealed that a TTS > 5 weeks was an independent predictor of decreased PFS (HR = 3.031, 95% CI: 1.494‐6.149, P = .002) but not OS. CONCLUSION: The longer TTS after the completion of NAC may be disadvantageous for a favorable pathological response and long‐term PFS. These results should be validated prospectively in a randomized trial. John Wiley and Sons Inc. 2020-09-04 /pmc/articles/PMC7643690/ /pubmed/32886456 http://dx.doi.org/10.1002/cam4.3283 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Chen, Qichen
Mao, Rui
Zhao, Jianjun
Bi, Xinyu
Li, Zhiyu
Huang, Zhen
Zhang, Yefan
Zhou, Jianguo
Zhao, Hong
Cai, Jianqiang
From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
title From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
title_full From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
title_fullStr From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
title_full_unstemmed From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
title_short From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
title_sort from the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: what is the optimal timing?
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643690/
https://www.ncbi.nlm.nih.gov/pubmed/32886456
http://dx.doi.org/10.1002/cam4.3283
work_keys_str_mv AT chenqichen fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT maorui fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT zhaojianjun fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT bixinyu fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT lizhiyu fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT huangzhen fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT zhangyefan fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT zhoujianguo fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT zhaohong fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming
AT caijianqiang fromthecompletionofneoadjuvantchemotherapytosurgeryforcolorectalcancerlivermetastasiswhatistheoptimaltiming